Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes

By sjmartinez • March 5, 2025

Mariette X, Borchmann S, Aspeslagh S, Szekanecz Z, Charles-Schoeman C, Schreiber S, Choy EH, Peyrin-Biroulet L, Schmalzing M, Tanaka Y, Ten Cate H, Westhovens R, van der Woude CJ, Ekoka Omoruyi EV, Faes M, Masior T, Van Hoek P, Watson C, Rudolph C, Stallmach A. Major adverse cardiovascular, thromboembolic and malignancy events in the filgotinib rheumatoid arthritis and ulcerative colitis clinical development programmes. RMD Open. 2025 Mar 4;11(1):e005033. doi: 10.1136/rmdopen-2024-005033. PMID: 40037922; PMCID: PMC11881192.

Tags: Antirheumatic Agents, Arthritis, Inflammation, Publications, Rheumatoid, Rheumatology

Depression and Inflammation in Women with Breast Cancer: Risk and Resilience Factors

Korecki JRT, Slavich GM, Ganz PA, Irwin MR, Cole S, Crespi CM, Bower JE. Depression and Inflammation in Women with Breast Cancer: Risk and Resilience[...]

From embedded interprofessional clinics to expanded alcohol-associated liver disease programs

Winder GS, Arab JP, Goswami Banerjee A, Bryce K, Fipps DC, Hussain F, Im G, Omary L, Patel AA, Patel S, Rubman S, Serper M,[...]

Understanding Transient Left Ventricular Ejection Fraction Reduction During Atrial Fibrillation With Artificial Intelligence

Yuan N, Hong GJ, Vrudhula A, Kwan AC, Duffy G, Botting P, Dhruva SS, Siegel RJ, Ouyang D. Understanding Transient Left Ventricular Ejection Fraction Reduction[...]